Codon-Optimized Complement Factor I for Lower-Dose Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for complement-mediated disorders such as age-related macular degeneration (AMD) are inadequate, particularly for conditions associated with overactivity of the complement C3b feedback cycle, and there is a need for new gene therapy approaches that can provide long-term, stable protein expression without repeated injections.
Innovation Solution
Codon-optimized sequences for Complement Factor I (CFI) and Complement Factor H-like Protein 1 (FHL1) are developed, enabling higher protein expression with lower vector doses, reducing tissue damage and off-target effects, and allowing for a single-dose, long-term therapeutic effect.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If higher vector doses are administered to achieve sufficient protein expression, then therapeutic effect is improved, but tissue damage and off-target effects increase
Solution Approach 1:
The patent applies codon optimization to change the nucleotide sequence parameters while maintaining the same amino acid sequence. This optimization changes the gene expression parameters to achieve higher protein production efficiency, allowing lower vector doses to achieve the same therapeutic effect, thereby reducing tissue damage and off-target effects
2Reliability
If higher vector doses are administered to achieve sufficient protein expression, then therapeutic effect is improved, but off-target effects increase
Solution Approach 1:
The patent uses codon optimization to improve the expression parameters of the therapeutic gene, enabling sufficient protein expression at lower vector doses. This reduces the spread of vector material to adjacent tissues, thereby minimizing off-target effects while maintaining therapeutic efficacy
3Duration of action of moving object
If repeated injections are administered to maintain protein expression, then therapeutic effect is maintained, but treatment complexity and patient burden increase
Solution Approach 1:
The patent employs codon-optimized sequences that enable the patient's own cells to continuously produce the therapeutic protein after a single vector administration. The optimized gene expression system allows the body to self-sustain therapeutic protein levels without requiring repeated external injections, reducing treatment complexity and patient burden
Data Source
AI summary
An isolated polynucleotide comprising a nucleotide sequence encoding a codon-optimised Complement Factor I (CFI).